Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker LGND
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 500 | $320.20 | $160.1K Sale | Form 4 ↗ |
| Nov 10, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 500 | $320.10 | $160.1K Sale | Form 4 ↗ |
| Nov 10, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 10 | $320.02 | $3,200 Sale | Form 4 ↗ |
| Nov 10, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 646 | $320.00 | $206.7K Sale | Form 4 ↗ |
| Nov 10, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 844 | $320.00 | $270.1K Sale | Form 4 ↗ |
| Nov 10, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 500 | $319.99 | $160.0K Sale | Form 4 ↗ |
| Nov 4, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 282 | $319.99 | $90.2K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 120 | $323.14 | $38.8K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 200 | $321.44 | $64.3K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 320 | $319.97 | $102.4K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 440 | $318.73 | $140.2K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 280 | $317.91 | $89.0K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 80 | $314.58 | $25.2K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 403 | $313.75 | $126.4K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 634 | $312.85 | $198.3K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 520 | $311.72 | $162.1K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 490 | $310.61 | $152.2K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 522 | $309.91 | $161.8K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 708 | $308.43 | $218.4K Sale | Form 4 ↗ |
| Nov 2, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 283 | $307.39 | $87.0K Sale | Form 4 ↗ |
| Nov 2, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 700 | $320.43 | $224.3K Sale | Form 4 ↗ |
| Oct 30, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 50 | $320.49 | $16.0K Sale | Form 4 ↗ |
| Oct 30, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 1,209 | $320.42 | $387.4K Sale | Form 4 ↗ |
| Oct 30, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 52 | $320.24 | $16.7K Sale | Form 4 ↗ |
| Oct 30, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 50 | $318.23 | $15.9K Sale | Form 4 ↗ |
| Oct 30, 2026 | Jason Aryeh Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 50 | $317.74 | $15.9K Sale | Form 4 ↗ |
| Sep 10, 2026 | Martine Zimmermann Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 1,200 | $285.00 | $342.0K Sale | Form 4 ↗ |
| Sep 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 400 | $288.98 | $115.6K Sale | Form 4 ↗ |
| Sep 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 385 | $287.53 | $110.7K Sale | Form 4 ↗ |
| Sep 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 2,115 | $286.36 | $605.7K Sale | Form 4 ↗ |
| Sep 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 1,800 | $285.17 | $513.3K Sale | Form 4 ↗ |
| Sep 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 300 | $283.99 | $85.2K Sale | Form 4 ↗ |
| Aug 12, 2026 | Octavio Espinoza Chief Financial Officer | LGND Ligand Pharmaceuticals Incorporated | Sale | 31,641 | $292.07 | $9.2M Sale | Form 4 ↗ |
| Aug 12, 2026 | Jason Haas Director | LGND Ligand Pharmaceuticals Incorporated | Sale | 7,138 | $292.81 | $2.1M Sale | Form 4 ↗ |
| Aug 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 409 | $292.82 | $119.8K Sale | Form 4 ↗ |
| Aug 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 991 | $291.71 | $289.1K Sale | Form 4 ↗ |
| Aug 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 200 | $290.60 | $58.1K Sale | Form 4 ↗ |
| Aug 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 503 | $289.80 | $145.8K Sale | Form 4 ↗ |
| Aug 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 356 | $288.75 | $102.8K Sale | Form 4 ↗ |
| Aug 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 1,214 | $287.77 | $349.4K Sale | Form 4 ↗ |
| Aug 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 1,032 | $286.80 | $296.0K Sale | Form 4 ↗ |
| Aug 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 157 | $285.74 | $44.9K Sale | Form 4 ↗ |
| Aug 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 33 | $284.55 | $9,390 Sale | Form 4 ↗ |
| Aug 3, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 105 | $284.14 | $29.8K Sale | Form 4 ↗ |
| Jul 1, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 600 | $317.15 | $190.3K Sale | Form 4 ↗ |
| Jul 1, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 900 | $315.78 | $284.2K Sale | Form 4 ↗ |
| Jul 1, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 100 | $314.58 | $31.5K Sale | Form 4 ↗ |
| Jul 1, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 700 | $313.46 | $219.4K Sale | Form 4 ↗ |
| Jul 1, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 1,081 | $312.28 | $337.6K Sale | Form 4 ↗ |
| Jul 1, 2026 | Andrew Reardon CLO & Secretary | LGND Ligand Pharmaceuticals Incorporated | Sale | 1,119 | $311.72 | $348.8K Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:54 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances